Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Let’s break down the Science of the Published ar

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155038
(Total Views: 968)
Posted On: 11/20/2021 12:55:05 PM
Posted By: Firelife619
Let’s break down the Science of the Published article:

Who is Frontiers in Immunology?

“Our journals are led and peer-reviewed by editorial boards of over 100,000 top researchers. Covering more than 900 academic disciplines, we are one of the largest and highest-cited publishers in the world. To date, our freely accessible research articles have received over 1 billion views and downloads and 1.6 million citations.”

Title:
CCR5 Receptor Occupancy Analysis
- Just this part of the title means the receptor occupancy analysis is done.

What does it reveal?
- Increased (Peripheral Blood) CCR5+CD4+ T Cells *because of* Leronlimab

Two independent, methods calculated the Receptor Occupancy.

Weekly (injections of) Leronlimab led to increased CCR5+CD4+ T cells levels which lead to Suppression of the virus in the blood).

Both Receptor Occupancy methods show that the cells were protected from viral replication because of Leronlimab.

Maraviroc CCR5 RO is indirectly measured, and is taken by a percentage in their method of measuring only 25%. Some reports of 120% CCR5 RO shows the inaccuracy.

I believe that any trial with Long Hauler regarding the CCR5 (or using Maraviroc) will not be approved; (thus, not promotable for this indication) because no CCR5 RO test for that drug exists.

Basically, the RO for Maraviroc is unclear.

Therefore, any FUD from short posters about “amazing” results of a “trial” with Maraviroc won’t do them any good without an RO.

-Oh, how the tables have turned.-

In the LH study, we got the double blinded Receptor Occupancy assay data from 8 patients.

The CCR5 RO assay correctly identified individuals treated with Leronlimab versus placebo.

In summary, CytoDyn has created and validated two different methods of calculating CCR5 RO for Leronlimab.

If the FDA was asking for 1 Receptor Occupancy, it looks like we will be sending TWO formulas that work.

BULLISH and enjoy your weekend

Sorry for me being upset a while back. Many reached out, I think i become very irritable with LH and sifting through responses on some soft bashers here can be a lot.


(26)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us